Drugs / BCD-132
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03551275 | Feb → Oct 2018 | multiple sclerosis | Biocad | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04056897 | Jun 2019 → Jul 2020 | multiple sclerosis | Biocad | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05385744 | Apr 2021 → Sep 2022 | multiple sclerosis | Biocad | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03551275 ↗ |
| Modality | Monoclonal antibody | “BCD-132 is a humanized monoclonal antibody against CD20.” NCT03551275 ↗ |
| Route | Intravenous | “single intravenous infusion of BCD-132 at the dose of 100 mg” NCT03551275 ↗ |